Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates by Bowman, Joel C et al.
Grand Valley State University
ScholarWorks@GVSU
Peer Reviewed Articles Physician Assistant Studies
11-1997
Expression of protein kinase C beta in the heart
causes hypertrophy in adult mice and sudden death
in neonates
Joel C. Bowman
Albert Einstein College of Medicine
Susan F. Steinberg
Columbia University
Tiangrong Jiang
Columbia University
David L. Geenen
Grand Valley State University, geenend@gvsu.edu
Glenn I. Fishman
Albert Einstein College of Medicine
See next page for additional authors
Follow this and additional works at: https://scholarworks.gvsu.edu/pas_articles
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Physician Assistant Studies at ScholarWorks@GVSU. It has been accepted for inclusion in
Peer Reviewed Articles by an authorized administrator of ScholarWorks@GVSU. For more information, please contact scholarworks@gvsu.edu.
Recommended Citation
Bowman, Joel C.; Steinberg, Susan F.; Jiang, Tiangrong; Geenen, David L.; Fishman, Glenn I.; and Buttrick, Peter M., "Expression of
protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates" (1997). Peer Reviewed Articles. 4.
https://scholarworks.gvsu.edu/pas_articles/4
Authors
Joel C. Bowman, Susan F. Steinberg, Tiangrong Jiang, David L. Geenen, Glenn I. Fishman, and Peter M.
Buttrick
This article is available at ScholarWorks@GVSU: https://scholarworks.gvsu.edu/pas_articles/4
 Expression of PKC
 
b
 
 in the Heart
 
2189
 
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/97/11/2189/07 $2.00
Volume 100, Number 9, November 1997, 2189–2195
http://www.jci.org
 
Expression of Protein Kinase C 
 
b
 
 in the Heart Causes Hypertrophy in Adult Mice
and Sudden Death in Neonates
 
Joel C. Bowman,* Susan F. Steinberg,
 
‡§
 
 Tiangrong Jiang,
 
‡
 
 David L. Geenen,* Glenn I. Fishman,* and Peter M. Buttrick*
 
*
 
Section of Molecular Cardiology and Department of Medicine, Albert Einstein College of Medicine, New York 10461; and 
 
‡
 
Department 
of Pharmacology and 
 
§
 
Department of Medicine, Columbia University, New York 10032
 
Abstract
 
Protein kinase C (PKC) activation in the heart has been
linked to a hypertrophic phenotype and to processes that in-
fluence contractile function. To establish whether PKC acti-
vation is sufficient to induce an abnormal phenotype, PKC
 
b
 
was conditionally expressed in cardiomyocytes of trans-
genic mice. Transgene expression in adults caused mild and
progressive ventricular hypertrophy associated with im-
paired diastolic relaxation, whereas expression in newborns
caused sudden death associated with marked abnormalities
in the regulation of intracellular calcium. Thus, the PKC
signaling pathway in cardiocytes has different effects de-
pending on the timing of expression and, in the adult, is suf-
ficient to induce pathologic hypertrophy. (
 
J. Clin. Invest.
 
1997. 100:2189–2195.) Key words: cardiac hypertrophy 
 
• 
 
pro-
tein kinase C 
 
• 
 
calcium handling 
 
•
 
 conditional transgenic
 
Introduction
 
Protein kinase C (PKC)
 
1
 
 comprises a family of serine/threo-
nine kinases that influence a variety of cellular functions. In
ventricular cardiocytes, specific isoforms are activated by a
number of putative hypertrophic stimuli, including 
 
a
 
1
 
-adrener-
gic agonists (1, 2), mechanical stretch (3, 4), angiotensin II (5),
and endothelin (6, 7). Intracellular PKC phosphorylation tar-
gets include proteins in the sarcolemma and sarcoplasmic
reticulum that regulate calcium homeostasis as well as sarco-
meric proteins that influence the calcium sensitivity of the con-
tractile machinery (8–12). In addition, PKC has been impli-
cated in the modulation of cardiac gene expression and in the
induction of cardiac hypertrophy (13–15). While there has
been progress towards identifying specific PKC isoform func-
tions in cultured cells, a direct link between enzyme activation
and altered myocyte function in the in vivo context has not
been established.
To address this, we have developed a binary transgenic
mouse model in which a constitutively active PKC
 
b
 
 isoform
can be conditionally expressed in the heart. Transient transfec-
tion of cultured cardiocytes with this same construct results in
transcriptional transactivation of genes, atrial natriuretic factor
(ANF), and 
 
b
 
 myosin heavy chain, which are characteristically
activated in pathologic cardiac hypertrophy (16–18). In addi-
tion, abnormal expression of PKC
 
b
 
 has been described in the
hearts of animals and humans subjected to pathologic loads
during postnatal life (19, 20), although this remains controver-
sial. These lines of evidence suggest but do not establish a
causal link between kinase activation and cardiac adaptation.
 
Methods
 
Animal model.
 
The salient features of the model are shown in Fig.
1 
 
A
 
. Two lines of mice were generated using standard techniques in a
C57/Bl6 background. Cardiac myocyte specificity in one line is deter-
mined by a gene in which 
 
z 
 
2.9 kb of 5
 
9
 
 flanking sequence from the
rat 
 
a
 
 myosin heavy chain gene drives expression of the tetracycline-
controlled transactivator (tTA) (21–23). In the second line, the target
gene, under the control of a heptamerized tetracycline operator/CMV
minimal promoter, is a bovine PKC
 
b
 
 rendered constitutively active
by an internal deletion (aa 6–159) which includes the pseudosubstrate
and a portion of the C1 domains of the intact molecule (24). The gen-
eral strategy and the construct backbones have been described in de-
tail previously (23). The genotype of the offspring was determined ei-
ther by PCR (primers are shown below) or Southern blotting using
standard techniques.
Animals were crossed and subsequently were either maintained
on tetracycline (1 mg/ml in drinking water supplemented with 1% su-
crose) or were given no drug. To suppress neonatal gene expression,
tetracycline was administered to pregnant animals throughout gesta-
tion.
 
Physiologic measurements.
 
To assay in vivo hemodynamics, ani-
mals were anesthetized with isofluorene and intubated. A PE-10 fluid-
filled cannula attached to a pressure transducer (Statham Instruments,
Hato Rey, PR) was advanced into the right carotid artery to deter-
mine baseline arterial pressures. Subsequently the chest was opened
and a 2F micromanometer transducer (SPR-407; Millar Instruments,
Inc., Houston, TX) was inserted through the apex of the left ventricle
for the simultaneous determination of left ventricular pressure. A bo-
lus infusion of isoproterenol (0.1 ml of a 10
 
2
 
7
 
 M solution) was then
administered via the femoral vein while left ventricular pressure was
monitored.
Echocardiograms were obtained on anesthetized mice using a 7.5
MHz transducer (Hewlett Packard, Andover, MA). Left ventricular
end systolic and end diastolic dimensions and ejection fractions were
calculated from 2D directional M-mode tracings.
 
Analytic techniques.
 
RNA was purified from the hearts of binary
adult animals using Trizol Reagent (GIBCO BRL, Gaithersburg,
MD). RT-PCR was performed on RNA according to standard tech-
niques (Gene Amp RNA PCR kit; Perkin Elmer Corp., Norwalk,
CT). Primers for the PKC
 
b
 
 transgene (which flank the internal dele-
tion) were: sense, 5
 
9
 
-ATGGCTGACCCGGCCG; antisense, 5
 
9
 
-CTA-
AATGTTTCGTTCCACTCGGGG, and for the tTA transgene
(which recognize the transcriptional initiation site of the 
 
a
 
 myosin
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heavy chain gene and the splice acceptor region): sense, 5
 
9
 
-TCA-
GACCGAGATTTCTCCATCCC; antisense, 5
 
9
 
-CGATCAAAGGAC-
TCTGGTA. Amplification was done for 30 cycles and the annealing
temperature was 51
 
8
 
C. Products were electrophoresed on 2% agarose
gels and the amplified bands were visualized by ethidium bromide
staining.
RNA was run on formaldehyde denaturing gels and blotted using
standard techniques. After cross-linking, the filters were hybridized
using QuikHyb (Stratagene, La Jolla, CA), and exposed to film. cDNA
probes for the human slow sarcoplasmic reticular calcium-dependent
ATPase (SERCA2) and mouse atrial natriuretic peptide (ANF) were
provided by D. MacLennon (University of Toronto, Toronto, Canada)
and J. Seidman (Harvard Medical School, Boston, MA), respectively.
An oligonucleotide complementary to sequence within the 3
 
9
 
 un-
translated region of the mouse 
 
b
 
 myosin heavy chain gene was used,
5
 
9
 
-TGTTGCAAAGGCTCCAGGTCTGAGGGCTTC.
Cardiac muscle homogenates were extracted and immunoblotted
according to previously published methods (25). The antibody for
PKC
 
e
 
 was from D. Fabbro (Ciba-Geigy, Basel, Switzerland).
Myofibrillar ATPase assays on murine heart protein were per-
formed as previously described (26).
Histologic assessment was done on 5 
 
m
 
M formalin-fixed paraffin-
embedded sections stained with hematoxylin and eosin according to
standard techniques. The tissue sections were subjectively evaluated
by an experienced pathologist blinded as to animal genotype.
 
Intracellular calcium transient measurements.
 
To isolate cardio-
cytes from neonatal hearts, the tissue was initially washed in a dissoci-
ation solution containing (mM): NaCl 110, KCl 5.4, NaHCO
 
3
 
 4, MgCl
 
2
 
1.6, NaH
 
2
 
PO
 
4
 
 1.8, Hepes 20, glucose 5, 
 
l
 
-glutamine 4, taurine 10. The
muscle was then minced and bathed in the dissociation solution con-
taining 3 mg/ml trypsin and 5 mg/ml BSA and shaken in a 37
 
8
 
C water
bath for 15 min. Five successive digestion–trituration cycles were car-
ried out. The supernatant from the first was discarded and those from
the subsequent cycles were pooled and centrifuged. The pelleted cells
were resuspended in dissociation solution containing 5 mg/ml BSA.
Cells were analyzed within 5 h of preparation. The method for Fura-2
loading and measurement of calcium transients in neonatal cardio-
cytes has been described previously (27). Cells were isolated from the
hearts of six binary PKC/tTA and five single PKC transgenic animals.
The investigator performing the analysis was unaware of the geno-
type of the animals.
 
Statistical analysis.
 
Unless specifically noted, statistical differ-
ences among groups were determined by ANOVA, followed by a
Newman-Keul’s posthoc analysis. Survival data were analyzed using
the 
 
x
 
2
 
 statistic (28). Significance is reported at the 0.05 level.
 
Results
 
PKC
 
b
 
 expression in animals harboring both transgenes should
be regulated by the absence or presence of exogenous tetracy-
cline and should be restricted to the cardiomyocytes. Data
demonstrating the fidelity of the binary system are illustrated
in Fig. 1 
 
B
 
 and demonstrate regulated expression of the PKC
 
b
 
gene in hearts from animals harboring both genes. The trans-
gene is expressed only in binary animals maintained in an un-
suppressed state, that is, off tetracycline.
To evaluate the effects of PKC
 
b
 
 overexpression, crosses
Figure 1. (A) Schematic 
illustration of the binary 
transgenic system used. 
The transactivator mouse 
expressed the tTA chi-
meric protein under the 
control of z 2.9 kb of the 
rat a myosin heavy chain 
promoter, whereas the 
target mouse harbored a 
constitutively active form 
of the bovine PKCb gene 
downstream of the tTA 
responsive promoter. (B) 
Reverse transcriptase 
PCR on cardiac tissue 
from binary transgenic 
animals maintained on or 
off tetracycline. Lanes
1–5 represent hearts 
from individual animals 
harboring both trans-
genes but not treated with 
tetracycline, whereas 
lanes 6–9 represent hearts 
from animals with an 
equivalent genotype but 
maintained on tetracy-
cline. PKCb mRNA (282 
bp) expression was only 
seen in untreated ani-
mals. A lane showing mo-
lecular weight markers 
(M) and a PCR positive 
control (1) are also 
shown.
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between animals homozygous for the PKC
 
b
 
 transgene and het-
erozygous for the tTA transgene were made (50% of the off-
spring would be predicted to harbor both transgenes and 50%
to harbor only PKC
 
b
 
). Animals were maintained on tetracy-
cline throughout gestation and through early postnatal life. At
8–10 wk of age the drug was discontinued in half of the ani-
mals. A cohort of animals was killed 4 wk after randomization.
A second cohort of animals was maintained for 5 mo and in
situ cardiac dimensions and performance were evaluated. In a
third group, the antibiotic was discontinued in all animals at
8 wk and the animals were subsequently maintained off tetra-
cycline for 9 mo. None died spontaneously. The animals were
killed at the various time points mentioned. Heart and body
weight comparisons were made in all groups and the animals
at the 5-mo time point underwent a more complete physiologic
evaluation.
 
Table I. Heart and Body Weights in Animals Off Tetracycline 
for 9 mo (by Gender)
 
Genotype
 
n
 
Gender Heart wt Body wt Heart/ Body wt
 
mg g mg/g
 
Binary 5 Male 193
 
6
 
12* 32
 
6
 
1 5.68
 
6
 
0.37*
Single 3 Male 155
 
6
 
5 35
 
6
 
2 4.43
 
6
 
0.41
Binary 3 Female 145
 
6
 
17* 28
 
6
 
2 5.14
 
6
 
0.51
 
‡
 
Single 6 Female 120
 
6
 
18 26
 
6
 
1 4.51
 
6
 
0.25
Data are mean
 
6
 
SEM. Binary animals harbor both the tTA and the
PKC
 
b
 
 transgenes, whereas single animals harbor only the PKC
 
b
 
 trans-
gene. *
 
P
 
 
 
,
 
 0.05 and 
 
‡
 
P
 
 
 
,
 
 0.07 versus gender-matched single trans-
genics.
 
Table II. Heart and Body Weights and Left Ventricular 
Dimensions in Animals Off Tetracycline for 5 mo
 
Genotype Tet
 
n
 
Body wt
Heart/
Body wt LVEDD LVESD FxShort
 
g mg/g mm mm %
 
Binary Off 5 25
 
6
 
4 4.5
 
6
 
0.2*
 
‡
 
3.6
 
6
 
0.2 1.5
 
6
 
0.3 54
 
6
 
9
Single Off 5 27
 
6
 
5 3.8
 
6
 
0.2 3.5
 
6
 
0.3 1.6
 
6
 
0.2 55
 
6
 
8
Binary On 5 31
 
6
 
6 3.8
 
6
 
0.3 3.6
 
6
 
0.4 1.4
 
6
 
0.2 62
 
6
 
4
Single On 4 33
 
6
 
7* 3.7
 
6
 
0.2 3.6
 
6
 
0.1 1.5
 
6
 
0.2 55
 
6
 
6
Data are mean
 
6
 
SD. Animals were maintained on tetracycline (
 
Tet
 
) un-
til 8–10 wk of age at which point half were taken off the antibiotic. Ani-
mals were killed and measurements were made 5 mo later. *
 
P
 
 
 
,
 
 0.05 vs.
single/off; 
 
‡
 
P
 
 
 
,
 
 0.05 vs. binary/on. 
 
LVEDD
 
, Left ventricular diastolic
dimension; 
 
LVESD
 
, left ventricular end systolic dimension; 
 
FxShort
 
,
fractional shortening.
Figure 2. Representative hematoxylin and eosin–stained sections from 7-mo-old adult mouse hearts. A is a section from an animal harboring 
only the PKCb transgene and B is from a binary (PKCb and tTA) animal. The binary animal evidences mild cellular hypertrophy and no evi-
dence of interstitial fibrosis or cellular necrosis.
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9 mo after cessation of tetracycline, the binary animals had
a significant increase both in heart weight and in heart/body
weight ratio (Table I). There was a trend for this increase to be
more marked in males (25% increase in heart weight and 28%
increase in heart/body weight ratio) than in females (21% in-
crease in heart weight and 14% increase in heart/body weight
ratio), although this gender difference did not reach statistical
significance. This increase in heart size was gradual: in the group
killed 4 wk after randomization, the binary animals off tetracy-
cline had a slight (5%) increase in heart/body weight ratio
which was not statistically distinct from the matched tetracy-
cline-treated control groups (
 
P
 
 
 
, 
 
0.08 versus single PKC
 
b
 
transgenic animals maintained on tetracycline). 5 mo after ran-
domization, the heart/body weight ratios in the binary animals
off tetracycline were increased by z 20% over the single trans-
genic animals (Table II, P , 0.05 vs. other groups). In contrast,
there was no increase in this ratio in the binary animals main-
tained on tetracycline relative to their matched controls. In
contrast to the data shown in Table I, half of the binary and
single transgenic animals at this time point were maintained on
the antibiotic to control for any unanticipated effects of tetra-
cycline or sucrose on cardiac physiology or patterns of gene ex-
pression. The increase in body weight seen in these treated an-
imals likely reflects the sucrose added to the drinking water.
However, absolute heart weight was significantly increased by
11% in the untreated binary animals relative to the untreated
single transgenic group (113 vs. 102 mg, P , 0.05). The in-
crease in heart weight was not accompanied by significant
changes in internal left ventricular systolic or diastolic dimen-
sions determined by echocardiography, consistent with con-
centric left ventricular hypertrophy. Ejection fraction did not
differ among groups, which is not surprising as this is a rela-
tively insensitive, load-dependent measure of systolic function
and the predominant defect in the hearts of the PKCb express-
ing mice appears to be diastolic (see below). Histologic evalua-
tion (Fig. 2) confirmed the presence of mild myocyte hypertro-
phy and did not show any significant intercurrent pathology.
Conventional molecular markers of cardiac hypertrophy, an
increase in mRNA levels of ANF and b myosin heavy chain
and a decrease in SERCA2, were not seen and compensatory
changes in the abundance of PKC were not evident. In addi-
tion, calcium-dependent myofibrillar ATPase curves did not
differ between single and binary off-tetracycline animals.
The carotid arteries and left ventricles of the same adult
mice identified in Table II were cannulated and pressures be-
fore and after isoproterenol infusions were determined (Table
III and Fig. 3). Closed chest arterial pressures did not differ
among groups; however, open chest peak left ventricular pres-
sure and (2) dP/dtmax were depressed at baseline and this was
accentuated (and dP/dtmax was also reduced) in response to an
inotropic challenge with isoproterenol.
To assess the effects of transgene expression in early post-
natal life, tetracycline was discontinued at midgestation. Sur-
vival data from heterozygote tTA/PKC crosses are shown in
Fig. 4 (one in four would be predicted to harbor both trans-
genes). While animals maintained on tetracycline showed
no mortality (42/42 live births survived until adulthood), 16/65
(z 25%) of the untreated animals died within the first 3 wk of
life. Death was sudden and not heralded by evidence of inter-
current disease. The time course is consistent with gene ex-
pression driven by the a myosin heavy chain promoter (29,
30). The genotype of the off-tetracycline survivors was (PKCb/
Table III. Hemodynamics before and after Isoproterenol Infusion
Genotype Tet
HR BP LVP 1dP/dt 2dP/dt LVP 1dP/dt 2dP/dt
Closed chest Open chest, before isoproterenol Open chest, after isoproterenol
Binary Off 220669 9766 78623 14696399 13736479* 92613*‡ 16036370* 15646272*‡
Single Off 240610 90610 91612 18276247 18446401 133640 21036415 25356686
Binary On 200617 93612 9863 1766668 18376175 115623 18466157 22346286
Single On 218645 99618 91615 16986231 16826383 138615 18916196 24166511
Data are mean6SD. *P , 0.05 vs. single/off; ‡P , 0.05 vs. single/on. Animals (and n) are exactly the same as those shown in Table II. Tet, Tetracy-
cline; HR, heart rate; LVP, left ventricular pressure.
Figure 3. Representa-
tive pressure tracings 
(mmHg) from a binary 
transgenic either on (A) 
or off (B) tetracycline. 
The first panel in each 
composite shows closed 
chest arterial pressure, 
the second shows simulta-
neous left ventricular and 
aortic pressure (open 
chest), and the third 
shows left ventricular 
pressure after bolus infu-
sion of isoproterenol.
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tTA): 1/1 5 3; 2/1 5 19; 1/2 5 12; 2/2 5 15 (P , 0.02 by
x2 analysis). These facts strongly suggest that expression of the
constitutively active PKCb during the early postnatal period is
lethal. A second line of PKCb animals was also crossed with
the tTA transactivator mice and showed a similar dispropor-
tionate loss of binary animals in early postnatal life (0/12 ani-
mals from these crosses surviving to adulthood were binary
transgenic animals).
Since the cause of death in the binary transgenic animals
was presumed to be arrhythmic, myocytes were isolated from
5–8-d-old binary (tTA/PKC) or single (PKC) untreated ani-
mals and their ability to regulate intracellular calcium was com-
pared. There were no obvious microscopic differences in the
size of the cells isolated from these animals. The cells were
loaded with Fura-2 and calcium transients were monitored
over a range of stimulation rates (Fig. 5 B). Cardiocytes from
both groups show the typical rate-dependent increase in the
amplitude and decrease in the duration of the calcium tran-
Figure 4. Survival curves of heterozygote crosses indicating that
z 25% of live births off tetracycline (dotted line) and none of those 
on tetracycline (solid line) died over the first 3 wk of life.
Figure 5. (A) Representative calcium transients from a PKCb expressing and nonexpressing myocyte (tTA/PKCb: 1/1 and 2/1). (B) At each 
stimulation rate, a series of six electrically driven calcium transients at steady state was signal averaged for analysis of the amplitude and duration 
at half-maximal amplitude of the calcium transient. Results of calcium measurements in 47 PKCb overexpressing and 37 nonexpressing cells are 
summarized (*P , 0.05 vs. matched values). (C) A representative record of typical calcium oscillations near the peak systolic value in control 
(top) and PKCb overexpressing myocytes (bottom).
2194 Bowman et al.
sient. However, the increase in amplitude was significantly at-
tenuated in myocytes from the binary animals at the most
rapid pacing rate and the duration was prolonged in these myo-
cytes at all pacing rates. The defect in the kinetics of relaxation
of the calcium transient led to secondary spikes that delayed
the return of intracellular calcium to baseline diastolic levels in
55% of cells from the binary animals (Fig. 5 C) and in none of
the cells from the single transgenic animals. In 19% of cells,
these ionic perturbations lasted for . 10 s.
Discussion
Two major questions are addressed by this study. The first is
whether expression of a single PKC isoform in the adult heart
is sufficient to effect a cardiac hypertrophic response and the
second is whether developmental context influences the physi-
ologic impact of gene expression. The use of the binary trans-
genic approach for conditional gene expression is ideally suited
to answer these questions since genes can be effectively tar-
geted to a specific cell type and expression can be temporally
defined. Previous studies using the binary system as well as
work from other laboratories using the same promoter indi-
cate that the level of cardiocyte protein expression varies
widely throughout the heart and may be at the limits of detec-
tion in as many as 40–50% of cells (31–33). In fact, we were un-
able to consistently detect PKCb protein expression in binary,
unsuppressed animals although we were able to detect mRNA.
These facts probably make this general approach impractical
for the manipulation of structural genes but it appears to be
well suited to modulated expression of regulatory enzymes,
such as PKC.
The fact that neonatal and adult cardiocytes manifest very
different responses to overexpression of the PKCb gene is not
surprising, although it suggests that extrapolation of data ac-
quired in fetal and neonatal cardiocytes to the adult heart must
be done with caution. Both PKC abundance and isoform dis-
tribution as well as the downstream components of the signal-
ing pathways activated by PKC are different in neonatal and
adult ventricular myocytes and it is also likely that different
transcription factors predominate in the different contexts (25,
34–36). In addition, it is quite possible that the activity of the
a myosin heavy chain promoter which drives expression of the
PKC transgene varies from neonatal to adult life. Beyond this,
and likely quite relevant to the phenotypes seen in our study,
there are marked developmental differences in the dominant
mechanisms that regulate calcium homeostasis. Relaxation of
the calcium transient in adult cardiocytes is largely accom-
plished by reuptake by the sarcoplasmic reticulum, whereas
the neonatal cardiocyte, which has a structurally and function-
ally immature sarcoplasmic reticulum, relies upon the sar-
colemmal Na1/Ca21 exchanger to extrude calcium during the
relaxation phase of the cardiac cycle (37, 38).
Our results suggest that sustained activation of PKC in the
absence of other intercurrent stimuli is sufficient to induce
concentric cardiac hypertrophy associated with a reduced ve-
locity of sarcomeric relaxation. The adaptation occurs, at least
at the stage at which mild ventricular hypertrophy is evident,
without demonstrable changes in ANF, b myosin heavy chain,
or SERCA2 mRNA expression nor with changes in sarco-
meric protein isoforms that would alter the calcium sensitivity
of the myofibril, demonstrating that these particular alter-
ations (all of which have been described in other models of
cardiac hypertrophy) are not necessary for the development of
a hypertrophic phenotype. A previous transgenic model, in
which p21ras was overexpressed in the postnatal heart, in-
duced a more dramatic hypertrophic phenotype with a similar
pattern of diastolic dysfunction which was associated with
transcriptional transactivation of the late response genes (39).
The identity of the etiologic PKC target(s) is not directly an-
swered, although the striking impairment in relaxation sug-
gests that abnormalities in the regulation of diastolic calcium, a
well described function of PKC activation (10, 40), may con-
tribute to the ultimate development of the cardiac adaptation.
This speculation is supported by an analysis both of genetic
models of cardiac hypertrophy (41, 42), which are character-
ized by alterations in the sarcomere length/tension relationship
which precede overt muscle failure, and acquired models of
cardiac hypertrophy (43–46) which manifest altered regulation
of diastolic calcium.
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